Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 20/20 | 0.66 |
| ▸ | PARP15 | Q460N3 | 7/20 | 0.59 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.59 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.59 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109845 | 0.84 | PARP10 (0.68) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| SCHEMBL28067530 | 0.81 | PARP10 (0.68) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| SCHEMBL9243500 | 0.81 | PKM (0.62) | ALDH1A1CA1CA2 | |
| SCHEMBL11099690 | 0.79 | PARP10 (0.66) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| SCHEMBL27925919 | 0.79 | PARP10 (0.66) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| SCHEMBL27526581 | 0.79 | L3MBTL1 (0.42) | PARP10ALDH1A1MAOB | |
| SCHEMBL13462623 | 0.79 | PARP10 (0.66) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| SCHEMBL1715535 | 0.79 | PRSS1 (0.70) | — | |
| SCHEMBL29960960 | 0.79 | PARP10 (1.00) | PARP10PARP15PARP4PARP14ALDH1A1 | |
| SCHEMBL27916544 | 0.79 | PARP10 (0.66) | PARP10PARP15PARP4PARP14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063093-B2 | Derivatives of 5-(halo)alkanoyl-6-hydroxy- benozofuran, benzothiophene, or indole; autoimmune diseases; systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis and psoriasis, transplant rejection; antiproliferative, anticarcinogenic, antidiabetic, antiinflammatory and antiulcer agents | HARVEY ANDREW J (AU) | 2011-11-22 | — | — | US | claimed |
| US-20080221194-A1 | Novel Potassium channel Blockers and Uses Thereof | HARVEY ANDREW J | 2008-09-11 | — | — | US | claimed |
| WO-2006096911-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | HARVEY ANDREW J (AU) | 2006-09-21 | — | — | WO | claimed |
| US-4001421-A | THIAZOLE CARDIOVASCULAR AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-01-04 | — | — | US | claimed |
| US-8063093-B2 | Derivatives of 5-(halo)alkanoyl-6-hydroxy- benozofuran, benzothiophene, or indole; autoimmune diseases; systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis and psoriasis, transplant rejection; antiproliferative, anticarcinogenic, antidiabetic, antiinflammatory and antiulcer agents | HARVEY ANDREW J (AU) | 2011-11-22 | — | — | US | disclosed |
| US-20080221194-A1 | Novel Potassium channel Blockers and Uses Thereof | HARVEY ANDREW J | 2008-09-11 | — | — | US | disclosed |
| CN-1599731-A | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2005-03-23 | — | — | CN | disclosed |
| US-4604481-A | Compounds for treatment or prophylaxis of cardiac disorders | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1986-08-05 | — | — | US | disclosed |
| US-4405642-A | BETA-BLOCKING AROMATIC ESTER COMPOUND | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1983-09-20 | — | — | US | disclosed |
| US-4391980-A | FOR INVERSION OF CONFIGURATION OF OPTICALLY ACTIVE COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1983-07-05 | — | — | US | disclosed |
| EP-0065964-A4 | METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1983-04-06 | — | — | EP | disclosed |
| EP-0065964-A1 | METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1982-12-08 | — | — | EP | disclosed |
| US-4294966-A | SALT FORMATION | CIBA-GEIGY CORPORATION (US) | 1981-10-13 | — | — | US | disclosed |
| US-4289883-A | ADRENERGIC BLOCKING AGENTS OF EXCELLENT CARDIOSELECTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-15 | — | — | US | disclosed |
| US-4210753-A | TREATMENT OF CARDIAC DISORDERS AND CHRONIC LUNG DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-01 | — | — | US | disclosed |
| EP-0007605-A1 | A process for inverting the configuration in optically active compounds and optically active intermediate compounds and their salts required therefor | CIBA-GEIGY AG (CH) | 1980-02-06 | — | — | EP | disclosed |
| US-4161530-A | CYCLIC SUBSTITUTED AMINO ALCOHOL BETA-RECEPTOR-BLOCKING AGENT AND TRYPTOPHANE | CIBA-GEIGY CORPORATION (US) | 1979-07-17 | — | — | US | disclosed |
| US-4147869-A | ADRENERGIC BLOCKING AGENTS FOR TREATMENT OF ANGINA PECTORIS, ARRHYTHMIA AND HYPERTENSION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1979-04-03 | — | — | US | disclosed |
| US-4089865-A | Certain thiazole compounds | SYNTEX (U.S.A.) INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4001421-A | THIAZOLE CARDIOVASCULAR AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221194-A1 | Novel Potassium channel Blockers and Uses Thereof | KCNAB1, KCNB1, KCNMB1 | PARP10 2309/4885PARP15 2584/4885PARP4 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.